Single-Use Bioreactors Have Reached the Big Time

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2017
Volume 2017 eBook
Issue 1
Pages: s13-s17

The decision to use disposable bioreactors is now driven by commercial rather than technological considerations.

Dramatic increases in protein titers from cell culture processes have enabled downsizing of upstream bioprocesses and facilitated the adoption of single-use bioreactors for biopharmaceutical manufacturing.

Manufacturers of disposable bioreactors have continually worked to improve their systems to meet evolving needs for biologic drug substance production.

This article explores recent advances in disposable bioreactor technology, the limitations that remain, and efforts that are underway to address them.

Download

Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook

.

 

 

 

Articles in this issue
SGS-Article_225.jpg
Clean, Disinfect, and Validate
Bioburden_225-1.jpg
Kill the Bioburden, Not the Biological Indicator
Cryoport_225.jpg
Cold Chain Logistics for Personalized Medicine: Dealing With Complexity
RawMaterials_225.jpg
Ensuring the Biological Integrity of Raw Materials
TechTransfer_225.jpg
Getting Biopharmaceutical Tech Transfer Right the First Time
Vetter_225.jpg
Developing an Injectable Compound for a Dual- Chamber Delivery System
GSK_225.jpg
Case Study: Retrofitting Two New High-Purity Water Systems
SUBioreactors_225.jpg
Single-Use Bioreactors Have Reached the Big Time
ParallelProcessing_225.jpg
Parallel Processing
Biosims_225.jpg
Cost Considerations Drive Lean Technology in Biomanufacturing
Recent Videos
Behind the Headlines episode 6
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Circio and Certest to Collaborate on LNP Formulations

Feliza Mirasol
November 21st 2024
Article

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

Feliza Mirasol
November 20th 2024
Article

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Frontier Scientific Solutions Plans a Global Free Trade Zone Gateway to Supply Life Sciences Industry on Back of $1.5 Billion Investment

Feliza Mirasol
November 16th 2024
Article

Frontier Scientific Solutions has unveiled plans to use a $1.5 billion commitment from a major investor to create a global free trade zone gateway to facilitate the life sciences supply chain using Wilmington International Airport in North Carolina.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Newly Opened Innovation Center in New Jersey Gives Avantor Advantage in Solving Life Sciences Challenges

Feliza Mirasol
November 15th 2024
Article

Avantor's newly launched expanded Innovation Center in Bridgewater, NJ, is designed for integrated workflows and features purpose-built collaboration spaces.